secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001437749-25-005468
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO Health reports Q4 net income of $14M, revenue $183.6M; BARDA/Merck milestones boost pharma
--------------------------------------------------------------------------------

- Consolidated Q4 revenue $183.6M vs $181.9M; net income $14.0M ($0.01 diluted EPS) vs net loss of $66.5M in Q4 2023.
- Pharma segment operating loss narrowed to $2.1M from $16.0M; IP transfer revenue rose to $43.1M (includes $12.5M Merck milestone, $23.8M BARDA).
- Diagnostics revenue fell to $103.1M from $124.2M on asset sales; operating loss improved to $21.7M from $42.3M.
- BARDA awarded additional $51M for COVID/influenza antibodies; total awards to ModeX now $110M, up to $205M if all options exercised.
- Capital actions: repurchased $17M principal notes, 10.9M shares for $16.5M; reduced share count 10% in 2024; sold part of BioReference for $237.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000143774925005468/0001437749-25-005468-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000143774925005468/opk20250103_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-005468

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer